Top ▲

Interleukin-1 receptor-like 2

Click here for help

Immunopharmacology Ligand  Target has curated data in GtoImmuPdb

Target id: 1736

Nomenclature: Interleukin-1 receptor-like 2

Family: Immunoglobulin-like family of IL-1 receptors

Contents:

Quaternary Structure: Complexes
Interleukin-36 receptor
Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 575 2q12.1 IL1RL2 interleukin 1 receptor like 2
Mouse 1 574 1 B Il1rl2 interleukin 1 receptor-like 2
Rat 1 561 9q22 Il1rl2 interleukin 1 receptor-like 2
Previous and Unofficial Names Click here for help
IL1RRP2 | interleukin-1 receptor-related protein 2
Database Links Click here for help
Alphafold Q9HB29 (Hs), Q9ERS7 (Mm), Q62929 (Rn)
CATH/Gene3D 2.60.40.10, 3.40.50.10140
ChEMBL Target CHEMBL4665591 (Hs)
Ensembl Gene ENSG00000115598 (Hs), ENSMUSG00000070942 (Mm), ENSRNOG00000014683 (Rn)
Entrez Gene 8808 (Hs), 107527 (Mm), 171106 (Rn)
Human Protein Atlas ENSG00000115598 (Hs)
KEGG Gene hsa:8808 (Hs), mmu:107527 (Mm), rno:171106 (Rn)
OMIM 604512 (Hs)
Pharos Q9HB29 (Hs)
UniProtKB Q9HB29 (Hs), Q9ERS7 (Mm), Q62929 (Rn)
Wikipedia IL1RL2 (Hs)

Download all structure-activity data for this target as a CSV file go icon to follow link

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
MAB92 Peptide Primary target of this compound Immunopharmacology Ligand Hs Antagonist 10.6 pKd 2
⤷ pKd 10.6 (Kd 2x10-11 M) [2]
Description: Binding affinity for recombinant hIL-36R by SPR
spesolimab Peptide Approved drug Immunopharmacology Ligand Hs Binding ~10.5 pKd 1
⤷ pKd ~10.5 (Kd ~3x10-11 M) [1]
Immunopharmacology Comments
Interleukin-1 receptor-like 2 is one of the subunits of the functional receptor for IL-36.

An antibody that mimics IL-36RA's antagonist activity at the IL-36 receptor (MAB92) has been described [2]. MAB92 inhibits proinflammatory cytokine production in primary human keratinocytes and dermal fibroblasts in vitro. Such IL-36 antagonist antibodies are predicted to present a novel therapeutic mechanism for the treatment of epithelial cell-mediated inflammation, in particular for DITRA (deficiency of IL-36 receptor antagonist) type syndromes caused by functionally inactivating mutations in IL-36RA which leave the pro-inflammatory activity of IL-36 receptor ligands unopposed.
Immuno Process Associations
Immuno Process:  Cytokine production & signalling
Immuno Process:  Inflammation
Immuno Process:  T cell (activation)
Immuno Process:  Immune regulation
Immuno Process:  Immune system development
Immuno Process:  Chemotaxis & migration
Immuno Process:  Cellular signalling

References

Show »

1. Brown SE, Canada K, Chlewicki L, Howell M, Mennerich D, Woska JR. (2015) Anti IL-36R antibodies. Patent number: US9023995B2. Assignee: Boehringer Ingelheim International GmbH. Priority date: 16/11/2011. Publication date: 05/05/2015.

2. Ganesan R, Raymond EL, Mennerich D, Woska Jr JR, Caviness G, Grimaldi C, Ahlberg J, Perez R, Roberts S, Yang D et al.. (2017) Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies. MAbs, 9 (7): 1143-1154. [PMID:28726542]

How to cite this page

Immunoglobulin-like family of IL-1 receptors: Interleukin-1 receptor-like 2. Last modified on 05/09/2022. Accessed on 24/04/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1736.